Latest Posters

With this poster, dive into the world of mass spectrometry troubleshooting, and discover detailed tables listing the accurate mass of elements, organic solvents and potential contaminant ions.

Obtaining enough synthetic mRNA for clinical use has long been a hurdle in treating conditions like cancer and infectious diseases.. Current mRNA production methods involve complex purification steps and chemicals, limiting large-scale manufacturing.

Biolayer Interferometry (BLI) technology has greatly advanced the process of antibody discovery, and the latest platforms offer reliable, high precision analysis which researchers can rely on.

This poster highlights several methods by which the downstream purification of viral vectors can be improved using chromatography methods to analyse and purify multiple AAV serotypes.

Recent advancements in affinity technology now support more robust and efficient Protein A chromatography. Hence, the latest Protein A solutions can enhance productivity, yield and accelerate products to market.

Despite the valuable transcriptomic information provided by probe-based spatial assays, detecting immune cell infiltration can pose challenges

There is more to DNA than A, C, G and T, epigenetics plays a causal role in cell fate, aging and disease development. Genetic and methylation data together on the same read allow us to get a more complete picture of genome biology. Constrained to measuring four states of information, existing NGS- based technologies sacrifice genetic for methylation calling.

Liquid biopsy for profiling of cell free DNA (cfDNA) in blood holds huge promise to transform how we experience and manage cancer by early detection and identification of residual disease and subtype. However, a standard blood draw yields an average of only 10 ng of cfDNA, of which DNA derived from the tumor is a small minority.

Affinity purification platforms such as Protein A or L are well-established in the manufacturing process of therapeutic monoclonal antibodies. However, with the development of engineered modalities such as bi-specific antibodies, fragments and Fc-fusion proteins, challenges in the downstream process of these molecules arise.

Designing and performing assays that accurately measure small molecule binding kinetics is an important part of the drug discovery process. It allows researchers to predict the efficacy of potential novel therapeutics and make quick decisions about weak binders.